Targeted Therapy (Antibody-Drug Conjugate)

22 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.

Connect With Us

+63 919 076 9100

Targeted Therapy (Antibody-Drug Conjugate) (9)

Quick filters: Solid Tumour Hematologic Both Name A-Z Name Z-A

Therapeutic Areas

Sort by

Clear all filters

Molecule	Drug Class / Mechanism	Oncology Type	Inquiry
Brentuximab Vedotin	ADC	Hematologic
Molecule Brentuximab Vedotin Therapeutic Category Targeted Therapy (Antibody-Drug Conjugate) Oncology Type Hematologic Drug Class / Mechanism ADC
Polatuzumab Vedotin	ADC	Hematologic
Molecule Polatuzumab Vedotin Therapeutic Category Targeted Therapy (Antibody-Drug Conjugate) Oncology Type Hematologic Drug Class / Mechanism ADC
Belantamab Mafodotin	ADC	Hematologic
Molecule Belantamab Mafodotin Therapeutic Category Targeted Therapy (Antibody-Drug Conjugate) Oncology Type Hematologic Drug Class / Mechanism ADC
Gemtuzumab Ozogamicin	ADC	Hematologic
Molecule Gemtuzumab Ozogamicin Therapeutic Category Targeted Therapy (Antibody-Drug Conjugate) Oncology Type Hematologic Drug Class / Mechanism ADC
Inotuzumab Ozogamicin	ADC	Hematologic
Molecule Inotuzumab Ozogamicin Therapeutic Category Targeted Therapy (Antibody-Drug Conjugate) Oncology Type Hematologic Drug Class / Mechanism ADC
Loncastuximab Tesirine	ADC	Hematologic
Molecule Loncastuximab Tesirine Therapeutic Category Targeted Therapy (Antibody-Drug Conjugate) Oncology Type Hematologic Drug Class / Mechanism ADC
Naratuximab Emtansine	ADC	Hematologic
Molecule Naratuximab Emtansine Therapeutic Category Targeted Therapy (Antibody-Drug Conjugate) Oncology Type Hematologic Drug Class / Mechanism ADC
Pivekimab Sunirine	Anti-CD123 ADC, DNA-alkylating payload	Hematologic
Molecule Pivekimab Sunirine Therapeutic Category Targeted Therapy (Antibody-Drug Conjugate) Oncology Type Hematologic Drug Class / Mechanism Anti-CD123 ADC, DNA-alkylating payload
Tafasitamab	ADC	Hematologic
Molecule Tafasitamab Therapeutic Category Targeted Therapy (Antibody-Drug Conjugate) Oncology Type Hematologic Drug Class / Mechanism ADC

Brentuximab Vedotin Targeted Therapy (Antibody-Drug Conjugate)
Therapeutic Category Targeted Therapy (Antibody-Drug Conjugate) Oncology Type Hematologic Drug Class / Mechanism ADC
Polatuzumab Vedotin Targeted Therapy (Antibody-Drug Conjugate)
Therapeutic Category Targeted Therapy (Antibody-Drug Conjugate) Oncology Type Hematologic Drug Class / Mechanism ADC
Belantamab Mafodotin Targeted Therapy (Antibody-Drug Conjugate)
Therapeutic Category Targeted Therapy (Antibody-Drug Conjugate) Oncology Type Hematologic Drug Class / Mechanism ADC
Gemtuzumab Ozogamicin Targeted Therapy (Antibody-Drug Conjugate)
Therapeutic Category Targeted Therapy (Antibody-Drug Conjugate) Oncology Type Hematologic Drug Class / Mechanism ADC
Inotuzumab Ozogamicin Targeted Therapy (Antibody-Drug Conjugate)
Therapeutic Category Targeted Therapy (Antibody-Drug Conjugate) Oncology Type Hematologic Drug Class / Mechanism ADC
Loncastuximab Tesirine Targeted Therapy (Antibody-Drug Conjugate)
Therapeutic Category Targeted Therapy (Antibody-Drug Conjugate) Oncology Type Hematologic Drug Class / Mechanism ADC
Naratuximab Emtansine Targeted Therapy (Antibody-Drug Conjugate)
Therapeutic Category Targeted Therapy (Antibody-Drug Conjugate) Oncology Type Hematologic Drug Class / Mechanism ADC
Pivekimab Sunirine Targeted Therapy (Antibody-Drug Conjugate)
Therapeutic Category Targeted Therapy (Antibody-Drug Conjugate) Oncology Type Hematologic Drug Class / Mechanism Anti-CD123 ADC, DNA-alkylating payload
Tafasitamab Targeted Therapy (Antibody-Drug Conjugate)
Therapeutic Category Targeted Therapy (Antibody-Drug Conjugate) Oncology Type Hematologic Drug Class / Mechanism ADC